TP53 and neoplasm: Feldmana et al. demonstrated next-generation sequencing of 224 tumor samples identified mutational hot spots corresponding to PI3KCA (26%), BRCA2 (21%), BRCA1 (10%), KRAS (10%), TP53 (10%), and FBXW7 (10%).